Celularity Incorporated Clinical Trials
Sponsors / Celularity Incorporated
ClinicalTrials.gov lists 11 trials for which Celularity Incorporated is named as lead sponsor. The portfolio currently includes 0 recruiting studies, 0 active non-recruiting studies, and 4 completed studies. 6 trials in this portfolio were terminated or withdrawn before completion. The most common reasons cited for termination include business or strategic decisions. Cumulative planned enrollment across all listed trials is 303 participants. These counts reflect the current state of the public ClinicalTrials.gov registry.
11
Total Trials
0
Recruiting
0
Other Active
4
Completed
6
Terminated / Withdrawn
303
Total Enrollment
Termination reasons: Other50% · Business50%
Recent Terminations
- Metastatic HER2 Positive Gastroesophageal Junction Cancer"for business reasons"
- Alkylating Agents"Business reasons"
- Analgesics"Business decision."
- Diabetic Foot"Business decision with all subjects completing at least 1 year follow-up"
- Leukemia, Myeloid, Acute"Business Decision"
- Stage 2 Pulmonary Sarcoidosis"Study Terminated by Sponsor"